Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LYT-100 BCRL, LYT-100
Deupirfenidone · 2 trials · 2 indications
Evaluate the efficacy of deupirfenidone compared with pirfenidone on reduction in lung function decline in participants with IPF
Rate of decline in Forced Vital Capacity (FVC; in mL)
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | deupirfenidone 825 mg TID |
| Active Comparator | ACTIVE_COMPARATOR | pirfenidone 801 mg TID |
| Placebo | PLACEBO_COMPARATOR | Placebo oral administration |
| pirfenidone 801 mg TID | ACTIVE_COMPARATOR | pirfenidone 801 mg TID oral administration |
| LYT-100 550 mg TID | EXPERIMENTAL | LYT-100 (Deupirfenidone) 550 mg TID oral administration |
| LYT-100 825 mg TID | EXPERIMENTAL | LYT-100 (Deupirfenidone) 825 mg TID oral administration |
| Name | Type | Description |
|---|---|---|
| Deupirfenidone | DRUG | size AA Swedish orange capsule |
| Pirfenidone (PFD) | DRUG | size AA Swedish orange capsule |
| Placebo | DRUG | placebo |
| Pirfenidone | DRUG | pirfenidone 801 mg TID |
Inclusion Criteria: * Is ≥40 years of age at the time of informed consent. * Meets the diagnostic criteria of IPF American Thoracic Society (ATS)/European Respiratory Society (ERS)/Japanese Respiratory Society (JRS)/Latin American Thoracic Society (ALAT) 2022 guidelines. * Has a maximum time from i...
Top 14 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 3 | PHASE3 | BMS-986278 |
| United Therapeutics Corporation | UTHR | 2 | PHASE3 | Tyvaso (treprostinil) |
| AbbVie, Inc. | ABBV | 2 | PHASE2 | ABBV-142 |
| Trevi Therapeutics, Inc. | TRVI | 2 | PHASE3 | Haduvio (nalbuphine ER) |
| Contineum Therapeutics, Inc. Class A | CTNM | 1 | PHASE2 | PIPE-791 |
| Insmed Incorporated | INSM | 1 | PHASE3 | Treprostinil Palmitil |
| Rein Therapeutics, Inc | RNTX | 1 | PHASE2 | LTI-03 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE2 | Axatilimab |
| Cumberland Pharmaceuticals Inc. | CPIX | 1 | PHASE2 | Ifetroban |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD8965 |
| Avalyn Pharma Inc | AVLN | 3 | PHASE2 | AP01, AP02 |
| MannKind Corporation | MNKD | 1 | PHASE2 | MNKD-201 |
| Vicore Pharma AB | VCRE | 1 | PHASE2 | Buloxibutid |
| AgomAb Therapeutics NV ADR | AGMB | 1 | PHASE2 | AGMB-447 |
Deupirfenidone is being developed for the treatment of idiopathic pulmonary fibrosis (IPF), a chronic lung disease. It is an investigational small molecule studied in adults aged 40 years and older with IPF. It has not been established as an approved therapy and remains in clinical development.
Deupirfenidone is being developed by PureTech Health plc, which trades under the ticker PRTCY. The company is advancing the small molecule through clinical development in idiopathic pulmonary fibrosis, with a Phase 3 trial currently recruiting and a Phase 2 trial ongoing.
Deupirfenidone is in Phase 3 development for idiopathic pulmonary fibrosis. Two clinical trials are active: a Phase 3 study comparing it to pirfenidone and a Phase 2 study. It is investigational and has not been approved by the FDA for any indication.
Deupirfenidone is being studied in two trials. NCT07284602 is a recruiting Phase 3 trial comparing LYT-100 (deupirfenidone) to pirfenidone in adults with IPF in the United States and Canada, enrolling 1,100 participants. NCT05321420 is a Phase 2 trial in IPF with 240 participants across multiple countries, now active but not recruiting.
Yes, deupirfenidone is also known as LYT-100. The Phase 3 trial is titled to evaluate LYT-100 (deupirfenidone) compared to pirfenidone in adults with idiopathic pulmonary fibrosis, and the Phase 2 trial is listed as LYT-100 in patients with IPF. Both names refer to the same investigational small molecule.
The Phase 3 trial, NCT07284602, is a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of deupirfenidone compared to pirfenidone in adults with idiopathic pulmonary fibrosis. It is recruiting participants aged 40 years and older in the United States and Canada, with planned enrollment of 1,100.